Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. - Université de Lille Accéder directement au contenu
Article Dans Une Revue Lancet Oncology Année : 2022

Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.

Fichier non déposé

Dates et versions

hal-04387055 , version 1 (11-01-2024)

Identifiants

Citer

Patricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, Christine Chevreau, Nicolas Penel, et al.. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.. Lancet Oncology, 2022, Lancet Oncology, ⟨10.1016/S1470-2045(22)00380-1⟩. ⟨hal-04387055⟩
9 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More